WO2023248206 - COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES
National phase entry is expected:
Publication Number
WO/2023/248206
Publication Date
28.12.2023
International Application No.
PCT/IB2023/056532
International Filing Date
24.06.2023
Title **
[English]
COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES
[French]
COMPOSITIONS ET MÉTHODES DE PRÉVENTION ET DE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
Applicants **
ARIBIO CO., LTD.
56, Dongpangyo-ro, Bundang-gu
Seongnam-si
Gyeonggi-do 13535, KR
Inventors
CHOUNG, Jai Jun
234 Hwangsaeul-ro 229 ho, Bundang-gu,
Seongnam-si
Gyeonggi-do, KR
SEO, Bo Seung
296 Sanbon-ro, Jugong 1 danji
Gunpo-si
Gyeonggi-do, KR
KANG, Byungwoo
131 Namhangseo-ro 1 dong 2306 ho,
Yeongdo-gu,
Busan, KR
Priority Data
63/367,033
24.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| Sequence Listing | * |
| International Search Report is established | *
International Searching Authority
KIPO
* |
| Applicant's Legal Status |
Legal Entity
* * * * * |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1091 | |
| EPO | Filing, Examination | 6798 | |
| Japan | Filing | 562 | |
| South Korea | Filing | 578 | |
| USA | Filing, Examination | 7435 |
Total: 16464 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase 5 inhibitor (PDE5 inhibitors) and an acetylcholinesterase inhibitor (AChEI) and a method using thereof, wehrein the PDE5 inhibitor is selected from among mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, pharmaceutically acceptable salts, solvates, hydrates, and a mixture thereof; and the AchEI is selected from among donepezil, rivastigmine, galantamine, physostigmine, tacrine, metrifonate, phenserine, tolserine, eseroline, huperizine A and B, galangin, cardanol, donepezil-AP2238, donepezil-tacrine, tacrine-ferulic acid hybrid, tacrine-hydroxyquinoline, ladostigil, indenyl derivatives, pharmaceutically acceptable salts, solvates, hydrates and a mixture thereof; and the neurodegenerative disease is dementia, Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD) or Multiple sclerosis (MS).[French]
La présente invention concerne une composition pour la prévention ou le traitement d'une maladie neurodégénérative contenant un inhibiteur de phosphodiestérase 5 (inhibiteurs de PDE5) et un inhibiteur d'acétylcholinestérase (AChEI) et une méthode d'utilisation de celle-ci, l'inhibiteur de PDE5 étant choisi parmi le mirodénafil, le sildénafil, le vardénafil, le tadalafil, l'udénafil, le dasantafil, l'avanafil, des sels, des solvates, des hydrates pharmaceutiquement acceptables et un mélange de ceux-ci ; et l'AchEI étant choisi parmi le donépezil, la rivastigmine, la galantamine, la physostigmine, la tacrine, le métrifonate, la phénsérine, la tolsérine, l'éséroline, l'hupérizine A et B, la galangine, le cardanol, le donépézil-AP2238, le donépézil-tacrine, l'hybride tacrine-acide férulique, la tacrine-hydroxyquinoline, le ladostigil, les dérivés d'indényle, des sels, des solvates, des hydrates pharmaceutiquement acceptables et un mélange de ceux-ci ; et la maladie neurodégénérative étant la démence, la maladie de Parkinson (PD), la maladie d'Alzheimer (AD), la maladie de Huntington (HD) ou la sclérose en plaques (MS).